SEARCH

SEARCH BY CITATION

References

  • 1
    Loeffen R, Spronk HMH, ten Cate H. The impact of blood coagulability on atherosclerosis and cardiovascular disease. J Thromb Haemost 2012; 10: 120716.
  • 2
    Darby SC, Kan SW, Spooner RJ, Giangrande PLF, Hill FGH, Hay CRM, Lee CA, Ludlam CA, Williams M. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 81525.
  • 3
    Triemstra M, Rosendaal FR, Smit C, van der Ploeg HM, Briët E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995; 123: 8237.
  • 4
    Srámek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003; 362: 3514.
  • 5
    Bilora F, Zanon E, Petrobelli F, Cavraro M, Prandoni P, Pagnan A, Girolami A. Does hemophilia protect against atherosclerosis? A case-control study. Clin Appl Thromb Hemost 2006; 12: 1938.
  • 6
    Biere-Rafi S, Tuinenburg A, Haak BW, Peters M, Huijgen R, de Groot E, Verhamme P, Peerlinck K, Visseren FLJ, Kruip MJHA, Laros-van Gorkom BAP, Gerdes VEA, Büller HR, Schutgens REG, Kamphuisen PW. Factor VIII deficiency does not protect against atherosclerosis. J Thromb Haemost 2012; 10: 307.
  • 7
    Biere-Rafi S, Zwiers M, Peters M, van der Meer J, Rosendaal FR, Büller HR, Kamphuisen PW. The effect of haemophilia and von Willebrand disease on arterial thrombosis: a systematic review. Neth J Med 2010; 68: 20714.
  • 8
    Foley CJ, Nichols L, Jeong K, Moore CG, Ragni MV. Coronary atherosclerosis and cardiovascular mortality in hemophilia. J Thromb Haemost 2010; 8: 20811.
  • 9
    Tuinenburg A, Rutten A, Kavousi M, Leebeek FWG, Ypma PF, Laros-van Gorkom BAP, Nijziel MR, Kamphuisen PW, Mauser-Bunschoten EP, Roosendaal G, Biesma DH, van der Lugt A, Hofman A, Witteman JCM, Bots ML, Schutgens REG. Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 799804.
  • 10
    Zwiers M, Lefrandt JD, Mulder DJ, Smit AJ, Gans ROB, Vliegenthart R, Brands-Nijenhuis AVM, Kluin-Nelemans JC, Meijer K. Coronary artery calcification score and carotid intima media thickness in patients with haemophilia. J Thromb Haemost 2012; 10: 239.
  • 11
    Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 283943.
  • 12
    Wilcox JN, Noguchi S, Casanova J. Extrahepatic synthesis of factor VII in human atherosclerotic vessels. Arterioscler Thromb Vasc Biol 2003; 23: 13641.
  • 13
    Bini A, Fenoglio JJ, Mesa-Tejada R, Kudryk B, Kaplan KL. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies. Arteriosclerosis 1989; 9: 10921.
  • 14
    Smith EB, Keen GA, Grant A, Stirk C. Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990; 10: 26375.
  • 15
    Bini A, Mesa-Tejada R, Fenoglio JJ, Kudryk B, Kaplan KL. Immunohistochemical characterization of fibrin(ogen)-related antigens in human tissues using monoclonal antibodies. Lab Invest 1989; 60: 81421.
  • 16
    Borissoff JI, Heeneman S, Kilinc E, Kassák P, van Oerle R, Winckers K, Govers-Riemslag JWP, Hamulyak K, Hackeng TM, Daemen MJAP, ten Cate H, Spronk HMH. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010; 122: 82130.
  • 17
    Borissoff JI, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 174660.
  • 18
    Bea F, Kreuzer J, Preusch M, Schaab S, Isermann B, Rosenfeld ME, Katus H, Blessing E. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26: 278792.
  • 19
    Zhou Q, Bea F, Preusch M, Wang H, Isermann B, Shahzad K, Katus HA, Blessing E. Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban. Mediators Inflamm 2011; 2011: 1–9.
  • 20
    Kadoglou NPE, Moustardas P, Katsimpoulas M, Kapelouzou A, Kostomitsopoulos N, Schafer K, Kostakis A, Liapis CD. The beneficial effects of a direct thrombin inhibitor, dabigatran etexilate, on the development and stability of atherosclerotic lesions in apolipoprotein E-deficient mice: dabigatran etexilate and atherosclerosis. Cardiovasc Drugs Ther 2012; 26: 36774.
  • 21
    Borissoff JI, Loubele STBG, Leenders P, Soehnlein O, Koenen RR, van Oerle R, Hamulyák K, Heeneman S, Daemen MJAP, Weiler H, van Ryn J, Spronk HMH, ten Cate H. Direct thrombin inhibition by dabigatran protects against severe atherosclerosis progression in prothrombotic mice. Circulation 2010; 122: A19384 (abstract).